As a testament to both the rigor and importance of Dr. Brinton's science, her breakthrough research has been continuously funded by rigorously peer-reviewed grants from the National Institutes of Health and private foundations including the Eileen and Kenneth Norris Foundation, which named her laboratory, the Alzheimer’s Drug Discovery Foundation, the John D. French Foundation, the Whittier Foundation, the Paul Slavik Trust and the Alzheimer’s Association.  Her current funding sources include:

  • Allopregnanolone a Regenerative Therapy for Alzheimer's: FDA-Required Toxicology

National Institute on Aging (NIA)
U01AG047222
2014-2017
Principal Investigator

  • Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase I

National Institute on Aging (NIA)
UF1AG046148
2013-2016
Principal Investigator

  • Estrogen Receptor-beta phytoSERMs for Management of Menopause and Age - associated Memory Decline  

National Institute on Aging (NIA)
R01AG033288
2010-2015            
Co-Principal Investigator         

  • Perimenopause in Brain Aging and Alzheimer’s Disease    

National Institute on Aging (NIA) 
P01-AG026572
2009-2017        
Principal Investigator
Project Leader Administrative Core A, Project 1 and Project 5

  • Estrogen-Induced Neuroprotective Mitochondrial Mechanisms       

National Institute on Aging (NIA) 
R01-AG032236
2009 – 2016  
Principal Investigator

  • Alzheimer Disease Research Center

National Institute on Aging (NIA) 
2P50 AG005142
1997 – 2015  
Project 2 – Brinton
Principal Investigator

  • Predictive Systems Pharmacology to Identify and Develop Therapeutics Targeting Alzheimer's Disease Geno / Pheno Types

National Institute on Aging (NIA) 
R34 AG-14-017
2014 – 2016  
Principal Investigator